Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $198 from $166 and keeps a Neutral rating on the shares following the Q3 report. Citi views the shares as fairly valued but believes Krystal is well positioned into its 2026 pipeline readouts.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech Reports Strong Q3 2025 Performance
- Krystal Biotech’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Krystal Biotech price target raised to $220 from $216 at Chardan
- Positive Outlook for Krystal Biotech: Growth Potential Driven by Vyjuvek, Clinical Pipeline, and Global Expansion
- Krystal Biotech price target raised to $217 from $212 at Clear Street